Trial Profile
Duloxetine as adjunctive treatment of negative symptoms in patients with schizophrenia: a double blind and placebo controlled trial
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 01 Mar 2018
Price :
$35
*
At a glance
- Drugs Duloxetine (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Therapeutic Use
- 02 Mar 2016 New trial record
- 22 Feb 2016 Primary endpoint of change in the PANSS negative subscale score from baseline to week 8 has not been met, according to results published in the Pharmacopsychiatry.
- 22 Feb 2016 Results published in the Pharmacopsychiatry